ZFIN ID: ZDB-PUB-210207-9
Melanoma models for the next generation of therapies
Patton, E.E., Mueller, K.L., Adams, D.J., Anandasabapathy, N., Aplin, A.E., Bertolotto, C., Bosenberg, M., Ceol, C.J., Chi, P., Herlyn, M., Holmen, S.L., Karreth, F.A., Kaufman, C.K., Khan, S., Kobold, S., Leucci, E., Levy, C., Lombard, D.B., Lund, A.W., Marie, K.L., Marine, J.C., Marais, R., McMahon, M., Robles-Espinoza, C.D., Ronai, Z.A., Samuels, Y., Soengas, M.S., Villanueva, J., Weeraratna, A.T., White, R.M., Yeh, I., Zhu, J., Zon, L.I., Hurlbert, M.S., Merlino, G.
Date: 2021
Source: Cancer Cell   39(5): 610-631 (Review)
Registered Authors: Ceol, Craig, Patton, E. Elizabeth, White, Richard M., Zon, Leonard I.
Keywords: animal models, drug discovery, immunotherapy, melanoma, targeted therapy, therapeutics, tumor microenvironment
MeSH Terms: none
PubMed: 33545064 Full text @ Cancer Cell
There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.